TOLREMO therapeutics
Michael Wacker is an experienced life science entrepreneur and General Partner at BioMedPartners. Michael Wacker serves on the board of directors of various portfolio companies. In addition, he coaches start-ups in Switzerland for Innosuisse, the governmental commission of technology and innovation. Before joining BioMedPartners, Michael Wacker was founder and CSO of GlycoVaxyn (acquired by GSK) and chairman of Inositec (acquired by Vifor). He studied biochemistry and obtained his PhD in microbiology from the Swiss Federal Institute of Technology in Zurich.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
TOLREMO therapeutics
TOLREMO therapeutics is a developer of small molecules intended to target novel drug resistance pathways in cancer therapy.